Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: J Immunol. 2022 Mar 18;208(7):1595–1615. doi: 10.4049/jimmunol.2100439

FIGURE 8. Il22 deficiency protects against intra-amniotic Ureaplasma parvum-induced preterm birth and neonatal mortality.

FIGURE 8.

(A) Il22+/+ and Il22−/− mice were intra-amniotically injected with Ureaplasma parvum or SP4 broth (control) on 16.5 days post coitum (dpc) and monitored until delivery. (B) Preterm birth rates of Il22+/+ and Il22−/− mice intra-amniotically injected with Ureaplasma parvum (n = 10 per genotype) or control (n = 10 per genotype). (C) Gestational lengths of Il22+/+ and Il22−/− mice intra-amniotically injected with Ureaplasma parvum or control. Dotted line and pink box represent the cut-off for preterm birth (<18.5 dpc). (D) Mortality rates of neonates born to Il22+/+ and Il22−/− mice intra-amniotically injected with Ureaplasma parvum or control. (E) Kaplan-Meier survival curves representing survival at weeks 1, 2, and 3 of neonates born to Il22+/+ and Il22−/− mice intra-amniotically injected with Ureaplasma parvum or SP4 broth. P-values were determined using the Mantel-Cox test.